Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática

Background: Domperidone is widely prescribed in patients with gastrointestinal disorders but some cardiac adverse effects have been recently reported. Aim: To evaluate the risk of QT prolongation, ventricular arrhythmias and sudden cardiac death associated with the use of oral domperidone in adults...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Marzi,Marta, Weitz,Darío, Avila,Aylén, Molina,Gabriel, Caraballo,Lucía, Piskulic,Laura
Lenguaje:Spanish / Castilian
Publicado: Sociedad Médica de Santiago 2015
Materias:
Acceso en línea:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100002
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:scielo:S0034-98872015000100002
record_format dspace
spelling oai:scielo:S0034-988720150001000022015-08-11Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemáticaMarzi,MartaWeitz,DaríoAvila,AylénMolina,GabrielCaraballo,LucíaPiskulic,Laura Arrhythmias, cardiac Domperidone Long QT Review Background: Domperidone is widely prescribed in patients with gastrointestinal disorders but some cardiac adverse effects have been recently reported. Aim: To evaluate the risk of QT prolongation, ventricular arrhythmias and sudden cardiac death associated with the use of oral domperidone in adults without cancer. Material and Methods: Systematic searches in MEDLINE, LILACS, SciELO, the Cochrane Library and regulatory agencies websites were performed, followed by a manual search of cited references. The search strategy consisted of combining free and indexed text words without any date or language restriction. Results: Three case-control studies met the inclusion criteria; none of them evaluated QT interval prolongation. With low risk of bias, each study quantified the risk of ventricular arrhythmia or sudden cardiac death (VA/SCD). The odds ratios for these events in these studies were 4.7 (95% confidence interval (CI): 1.4-16), 1.59 (95% CI: 1.28-1.98) and 11.02 (95% CI: 2.02-62.3) respectively. A significantly increased risk was observed in patients older than 60 years of age or receiving doses > 30 mg/day. Conclusions: Heterogeneity between selected studies did not allow the computation of a summary measure. However, evidence was found that an increased risk of VA/SCD is associated with the use of oral domperidone in adults.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.143 n.1 20152015-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100002es10.4067/S0034-98872015000100002
institution Scielo Chile
collection Scielo Chile
language Spanish / Castilian
topic Arrhythmias, cardiac
Domperidone
Long QT
Review
spellingShingle Arrhythmias, cardiac
Domperidone
Long QT
Review
Marzi,Marta
Weitz,Darío
Avila,Aylén
Molina,Gabriel
Caraballo,Lucía
Piskulic,Laura
Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática
description Background: Domperidone is widely prescribed in patients with gastrointestinal disorders but some cardiac adverse effects have been recently reported. Aim: To evaluate the risk of QT prolongation, ventricular arrhythmias and sudden cardiac death associated with the use of oral domperidone in adults without cancer. Material and Methods: Systematic searches in MEDLINE, LILACS, SciELO, the Cochrane Library and regulatory agencies websites were performed, followed by a manual search of cited references. The search strategy consisted of combining free and indexed text words without any date or language restriction. Results: Three case-control studies met the inclusion criteria; none of them evaluated QT interval prolongation. With low risk of bias, each study quantified the risk of ventricular arrhythmia or sudden cardiac death (VA/SCD). The odds ratios for these events in these studies were 4.7 (95% confidence interval (CI): 1.4-16), 1.59 (95% CI: 1.28-1.98) and 11.02 (95% CI: 2.02-62.3) respectively. A significantly increased risk was observed in patients older than 60 years of age or receiving doses > 30 mg/day. Conclusions: Heterogeneity between selected studies did not allow the computation of a summary measure. However, evidence was found that an increased risk of VA/SCD is associated with the use of oral domperidone in adults.
author Marzi,Marta
Weitz,Darío
Avila,Aylén
Molina,Gabriel
Caraballo,Lucía
Piskulic,Laura
author_facet Marzi,Marta
Weitz,Darío
Avila,Aylén
Molina,Gabriel
Caraballo,Lucía
Piskulic,Laura
author_sort Marzi,Marta
title Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática
title_short Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática
title_full Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática
title_fullStr Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática
title_full_unstemmed Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática
title_sort efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática
publisher Sociedad Médica de Santiago
publishDate 2015
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100002
work_keys_str_mv AT marzimarta efectosadversoscardiacosdeladomperidonaenpacientesadultosrevisionsistematica
AT weitzdario efectosadversoscardiacosdeladomperidonaenpacientesadultosrevisionsistematica
AT avilaaylen efectosadversoscardiacosdeladomperidonaenpacientesadultosrevisionsistematica
AT molinagabriel efectosadversoscardiacosdeladomperidonaenpacientesadultosrevisionsistematica
AT caraballolucia efectosadversoscardiacosdeladomperidonaenpacientesadultosrevisionsistematica
AT piskuliclaura efectosadversoscardiacosdeladomperidonaenpacientesadultosrevisionsistematica
_version_ 1718436797310042112